

REMARKS

In view of the above amendments and the following remarks, reconsideration of the outstanding office action is respectfully traversed. Pursuant to 37 CFR § 1.21, attached as an Appendix is a Version With Markings to Show Changes Made.

The objection to claims 25, 26, and 29 is respectfully traversed in view of the above amendments.

The rejection of claims 27 and 28 under 35 U.S.C. § 112 (1st para.) for failure to satisfy the written description requirement is respectfully traversed in view of the cancellation of these claims.


The rejection of claims 19, 21, and 22 under 35 U.S.C. § 102 as anticipated by Armstrong, et. al., "Pre-Oligodendrocytes from Adult Human CNS," J. Neurosci. 12(4): 1538-47 (1992) is respectfully traversed in view of the cancellation of these claims.

The rejection of claims 19, 21, and 22 under 35 U.S.C. § 102 as anticipated by Kirschenbaum, et. al., "*In Vitro* Neuronal Production and Differentiation by Precursor Cells Derived from the Adult Human Forebrain," Cerebral Cortex 6: 576-89 (1994) is respectfully traversed in view of the cancellation of these claims.

In view of all the foregoing, it is submitted that this case is in condition for allowance and such allowance is earnestly solicited.

Respectfully submitted,

Date: March 24, 2003



Michael L. Goldman
Registration No. 30,727

NIXON PEABODY LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603
Telephone: (716) 263-1304
Facsimile: (716) 263-1600

Certificate of Mailing - 37 CFR 1.8(a)	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: U.S. Patent and Trademark Office P.O. BOX 2327 Arlington, VA 22202, on the date below.	
Date <u>3/24/03</u>	<u>Jane C. Wirszyka</u> Jane C. Wirszyka



APPENDIX
Version with Markings to Show Changes Made
Page 1 of 1

In reference to the amendments, additions appear as underlined text, while deletions appear as bracketed text, as indicated below:

In the Claims:

Please amend claim 29 as follows:

29. (Amended) An [The] enriched or purified preparation of human mitotic oligodendrocyte progenitor cells [according to claim 19], wherein an oligodendrocyte specific promoter functions in all cells of the enriched or purified preparation.